Cadila Pharmaceuticals (CPL) is a key research-based, tech-savvy pharmaceutical company focusing on different areas – formulations (human and veterinary), new drug discovery, novel drug delivery, active pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, biosynthesis, genetic engineering, vaccines amd immunoglobulins. Over the last few years, it has established a strong R&D base in biotechnology and developed working relations with key R&D institutes in the country.
About 20 products including conventional and recombinant vacancies, anti cancer biotherapeutics, diagnostics using recombinant antigens and natural thrombolites with high market potential are in its biotechnology basket. It has developed Immuvac, a potent, unique Immunomodulator for the first time in the world. Sodium Hyaluronate, is another biotech product developed on the basis of technology obtained from the Center for Biochemical Technology, Delhi. It has also launched Streptokinase under brand name STPase. About half dozen products are in the pipeline for immuno-prophylaxis, diagnosis of hepatitis C, therapeutics for cancer, viral hepatitis, diabetes mellitus and anaemia. Its biotechnology division has a very small contribution of Rs 17 crore during 2005-06, a marginal increase from last year's biotech sales of Rs 14 crore.